MFOHome About Commentary Discussions Funds The Best Resources Support Us!

Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Sign In Register

Categories

In this Discussion

  • Ted February 2016
Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.

    Support MFO

  • Donate through PayPal

Taymour R. Tamaddon to leave T Rowe Price Health Sciences Fund, but stays with T Rowe Price

TheShadowTheShadow
in Fund Discussions
http://www.sec.gov/Archives/edgar/data/918294/000100262416000017/hsfhsphsvstatutorystic-20163.htm

497 1 hsfhsphsvstatutorystic-20163.htm
T. Rowe Price Health Sciences Fund

T. Rowe Price Health Sciences Portfolio

T. Rowe Price Health Sciences Portfolio—II


Supplement to Prospectuses Dated May 1, 2015

In section 1, the portfolio manager table under “Management” is supplemented as follows:

Effective April 1, 2016, Ziad Bakri will join Taymour R. Tamaddon as the fund’s co-portfolio manager and co-chairman of the fund’s Investment Advisory Committee. Mr. Bakri joined T. Rowe Price in 2011. Effective July 1, 2016, Mr. Tamaddon will step down as portfolio manager and Mr. Bakri will become the fund’s sole portfolio manager and Chairman of the fund’s Investment Advisory Committee.

In section 3, the disclosure under “Portfolio Management” is supplemented as follows:

Effective April 1, 2016, Ziad Bakri will join Taymour R. Tamaddon as co-chairman of the fund’s Investment Advisory Committee. Mr. Bakri joined the Firm in 2011 and his investment experience dates from 2005. Since joining the Firm, he has served as an investment analyst covering the healthcare sector. Prior to joining the Firm, he was an equity research analyst with Cowen and Company and an investment banking analyst with Merrill Lynch. Effective July 1, 2016, Mr. Tamaddon will step down as co-chairman of the committee and Mr. Bakri will serve as sole chairman of the committee.


The date of this supplement is February 1, 2016.

F114-041 2/1/16


--------------------------------------------------------------------------------


Staying with T Rowe Price

T. Rowe Price Institutional Large-Cap Growth Fund

http://www.sec.gov/Archives/edgar/data/1012968/000101296816000014/lcvstatutorysticker211-20161.htm


497 1 lcvstatutorysticker211-20161.htm
T. Rowe Price Institutional Large-Cap Growth Fund


Supplement to Prospectus Dated May 1, 2015

On page 5, the portfolio manager table under “Management” is supplemented as follows:

Effective January 1, 2017, Taymour R. Tamaddon will replace Robert W. Sharps as the fund’s portfolio manager and Chairman of the fund’s Investment Advisory Committee. Mr. Tamaddon joined T. Rowe Price in 2004.

On page 21, the disclosure under “Portfolio Management” is supplemented as follows:

Effective June 30, 2016, Taymour R. Tamaddon will become a member of the fund’s Investment Advisory Committee and, effective January 1, 2017, Mr. Tamaddon will replace Robert W. Sharps as Chairman of the committee. Mr. Tamaddon joined the Firm in 2004 and his investment experience dates from 2003. Since joining the Firm, he has served as an equity research analyst and a portfolio manager (beginning in 2013).


The date of this supplement is February 1, 2016.

E139-041 2/1/16


--------------------------------------------------------------------------------

Comments

Sign In or Register to comment.